Vertex joins Merck, Pfizer — revamping multibillion-dollar trial strategy as biotech R&D crumbles
You can add Pfizer, Merck and — as we found out Friday morning — Vertex to the growing list of pharma giants hitting the pause button on a range of clinical trials. But not everyone in R&D is getting a red light.
Vertex says that it’s doing its best to keep working its pipeline strategy, coming up with a plan “to enable virtual clinic visits and home delivery of study drug to ensure study continuity and medical monitoring, and to facilitate study procedures.”
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 109,500+ biopharma pros reading Endpoints daily — and it's free.